Navigation Links
Stereotactic Body Radiation Therapy for Lung Cancer a Key Topic for Elekta Presenters at Annual ASTRO Conference
Date:7/19/2010

ATLANTA, July 19 /PRNewswire/ -- The American Society for Radiation Oncology (ASTRO) has accepted four abstracts from users of Elekta Stereotactic Body Radiation Therapy (SBRT) technology on the use of SBRT to treat non-small cell lung cancer (NSCLC). The clinicians will present their findings during presentations at ASTRO's 52nd Annual Meeting (October 31 - November 4) at the San Diego Convention Center.

NSCLC, the most common form of lung cancer, arises from a number of causes, including active smoking, passive smoking (secondhand smoke), asbestos and radon exposure. Lung cancer is the leading cause of cancer death in men and women. Each year, primary carcinoma of the lungs affects 93,000 men and 80,000 women in the United States and 86 percent die within five years of diagnosis. The incidence of lung cancer peaks between the ages 55 and 65.(1)

"The research in which our Lung Cancer Consortium is engaged is completely consistent with ASTRO's theme this year: Gathering Evidence; Proving Value," says Joel Goldwein, M.D., Senior Vice President and Director of Medical Affairs for Elekta. "The researchers have made a number of very important discoveries, some of which I believe will be likely to change how SBRT is administered to this challenging group of patients. It doesn't get much more valuable than that."

The four papers featuring Elekta technology are:

  1. Poor Pulmonary Function is not Associated with Increased Rates of Toxicity or Decreased Overall Survival after Stereotactic Body Radiotherapy for Early Stage Non-Small Cell Lung Cancer: Results of a Multi-Institutional Analysis: Matthias Guckenberger, M.D., Jose Belderbos, M.D., Ph.D., Andrew Hope, M.D., Larry L. Kestin, M.D., Maria Werner-Wasik, M.D., Jan-Jakob Sonke, Ph.D., Jean-Pierre Bissonnette, Ph.D., Ying Xiao, Ph.D., Di Yan, D.Sc., Inga S. Grills, M.D.
  2. A Collaborative Analysis of Stereotactic Lung Radiotherapy (Lung SBRT) Outcomes for Stage I Non-Small Cell Lung Cancer (NSCLC) using Daily Online Cone-beam CT Image-Guided Radiotherapy (CBCT-IGRT): Inga S. Grills, M.D., Andrew J. Hope, M.D., Matthias Guckenberger, M.D., Larry L. Kestin, M.D., Maria Werner-Wasik, M.D., Di Yan, D.Sc., Jan-Jakob Sonke, Ph.D., Jeanne-Pierre Bissonnette, Ph.D., Ying Xiao, Ph.D., Jose Belderbos, M.D.
  3. Time Interval Between Staging FDG Positron Emission Tomography (PET) and Initiation of Stereotactic Lung Radiotherapy (SBRT) Impacts the Risk of Recurrence and Metastasis in Non-Small Cell Lung Cancer (NSCLC): Jose Belderbos, M.D. Ph.D., Andrew Hope, M.D., Larry L. Kestin, M.D., Matthias Guckenberger, M.D., Maria Werner-Wasik, M.D., Jan-Jakob Sonke, Ph.D., Jean-Pierre Bissonnette, Ph.D., Ying Xiao, Ph.D., Di Yan, D.Sc., Inga S. Grills, M.D.
  4. Substantial Dose-Response Relationship with Clinical Outcome for Lung Stereotactic Body Radiotherapy (SBRT) Delivered Via Online Image Guidance: Larry Kestin M.D., Inga Grills, M.D., Matthias Guckenberger, M.D., Jose Belderbos, M.D., Andrew J. Hope, M.D., Maria Werner-Wasik, M.D., Jan-Jakob Sonke, Ph.D., Jeanne-Pierre Bissonnette, Ph.D., Ying Xiao, Ph.D., Di Yan, D.Sc.

The clinicians are affiliated with the University of Wurzburg, The Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital (NKI/AvL), Princess Margaret Hospital /  University Health Network, Thomas Jefferson University Hospital and William Beaumont Hospital.

Advanced Elekta SBRT technology used today includes Elekta Axesse™ and Elekta Synergy® S treatment systems and Symmetry™ and Intuity™ software. Symmetry is a breakthrough technology that enables highly accurate, yet completely non-invasive lung tumor treatments without requiring additional intra-fraction radiation imaging. Intuity ensures that not only is the tumor's position accounted for, but also the position of nearby healthy critical structures. Both innovations contribute to a more patient-friendly and safe treatment.

(1)Retrieved June 29, 2010 from the Cancer Monthly website: http://www.cancermonthly.com/cancer_basics/lung.asp

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.


'/>"/>
SOURCE Elekta
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Presentations at the Third European Stereotactic Radiation Therapy and Whole Body Radiotherapy Workshop Highlight Clinical Outcomes and Emerging Trends
2. Cumming Radiation Oncologist Performs First Stereotactic Body Radiation Therapy in Forsyth County
3. Obesity Significantly Increases Side Effects of Stereotactic Body Radiation Therapy in Lung Cancer Patients
4. New Research Shows Effectiveness of Stereotactic Body Radiotherapy for Spinal Tumors
5. Elektas New Line of Stereotactic Treatment Solutions is Redefining Excellence in Stereotaxy, a Case at a Time
6. Two Studies Evaluated Full-Dose Chemotherapy Regimen and Concurrent Radiation in Treatment of Lung Cancer
7. ECRI Institute(R) Issues Expanded Recommendations for Controlling CT Radiation Dose: Computed Tomography Dose is on the Institutes 2010 List of Top 10 Technology Hazards
8. Diablo Valley Oncology First Cancer Center in Northern California to Offer NEW Radiation Device
9. FDA Provides 510k Clearance for BARRX Medicals HALO90 Ablation Catheter for the Treatment of Radiation Proctitis and Gastric Antral Vascular Ectasia (GAVE)
10. US Oncology Ranks 2nd in Affiliate Member Accruals for Radiation Therapy Oncology Group
11. Is the Person Exposing You to Radiation Qualified?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 2, 2016 CVS Health Corporation (NYSE: ... Day in New York City on Thursday, December 15, 2016, beginning at 8:00 ... team will provide an in-depth review of the company,s ... The company will also discuss 2017 earnings guidance during ... of the event will be broadcast simultaneously on the ...
(Date:12/2/2016)... 2, 2016 Lianluo Smart Limited (Nasdaq: ... Company") which develops, markets and sells medical devices ... China and international markets, recently attended ... Treatment New Progress Forum, co-hosted by the Institute ... , Guangdong Provincial People,s Hospital and Cardiology ...
(Date:12/2/2016)... , December 2, 2016 On ... down 1.36%; the Dow Jones Industrial Average edged 0.36% higher, ... 2,191.08, down 0.35%. Losses were broad based as six out ... has initiated research reports on the following Services equities: Myriad ... QGEN ), INC Research Holdings Inc. (NASDAQ: ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... ... With the number of pain management programs available for people suffering with constant ... works for them. When an inventor from Suisun City, Calif., was unsuccessful in finding ... it with others. , He developed a prototype for PRO GO MASSAGE to relieve ...
(Date:12/2/2016)... ... December 02, 2016 , ... CloudLIMS.com, a class-leading provider of ... Lite. CloudLIMS Lite helps biobanks, clinical, research and testing laboratories keep track of ... new version is a faster and a more efficient product, allowing batch processing ...
(Date:12/2/2016)... ... 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, Texas, ... Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in 1934 ... details line up exactly with Bible Prophecy – a protected way for those who ...
(Date:12/2/2016)... ... December 02, 2016 , ... Date aired: November 28, ... 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein , Sharon Kleyne, America’s ... Global Climate Change and Your Health radio program syndicated on Voice of America, ...
(Date:11/30/2016)... Wisconsin (PRWEB) , ... November 30, 2016 , ... ... in the 2016 Deloitte Wisconsin 75, an annual ranking and recognition of the ... year on the list, having ranked from 2008-2016. In addition, Standard Process was ...
Breaking Medicine News(10 mins):